Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Pinter

Showing results (31-40 of 135) with videos related to

Pageof 14
Sort By:
Journal of Tissue Engineering and Regenerative Medicine|April 14, 2025
A Novel Epidermis Model Using Primary Hidradenitis Suppurativa KeratinocytesIsabel Haferland, Andreas Pinter, Tanja Rossmanith, et al.
The Journal of Dermatological Treatment|February 26, 2019
Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trialAndrew Blauvelt, Mark Lomaga, Russel Burge, et al.
Vaccines|August 28, 2021
Influenza Vaccination in Psoriatic Patients-Epidemiology and Patient Perceptions: A German Multicenter Study (Vac-Pso)Christian Kromer, Phoebe Wellmann, Ralf Siemer, et al.
Dermatology (Basel, Switzerland)|December 16, 2020
Coprevalence of Hidradenitis Suppurativa and Psoriasis: Detailed Demographic, Disease Severity and Comorbidity PatternAndreas Pinter, Mana Sarlak, Kim Nicola Zeiner, et al.
International Journal of Cancer|January 19, 2007
Simultaneous blockade of VEGFR-1 and VEGFR-2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formationJens Gille, Regina Heidenreich, Andreas Pinter, et al.
Dermatology and Therapy|June 6, 2020
Hidradenitis Suppurativa and Concurrent Psoriasis: Comparison of Epidemiology, Comorbidity Profiles, and Risk FactorsAndreas Pinter, Georgios Kokolakis, Juergen Rech, et al.
Dermatology and Therapy|May 10, 2024
Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) StudyAndreas Pinter, Ahmed M Soliman, Irina Pivneva, et al.
The Journal of Investigative Dermatology|March 8, 2008
Microtubule-targeted drugs inhibit VEGF receptor-2 expression by both transcriptional and post-transcriptional mechanismsMarkus Meissner, Andreas Pinter, Despina Michailidou, et al.
Dermatology (Basel, Switzerland)|May 21, 2026
PASI Training via Virtual Reality Application - new way of effective teachingSascha Gerd Decker, Falk Ochsendorf, Michael Gairing, et al.
Dermatology (Basel, Switzerland)|November 6, 2024
Brodalumab Is Effective for Psoriasis Patients with Difficult-To-Treat Body Regions: Results from an Observational Clinical StudyStephanie Dauth, Ann Christina Foldenauer, Konstantin Hallmann, et al.
Pageof 14

Showing results (31-40 of 135) with videos related to

Sort By:
Pageof 14
Journal of Tissue Engineering and Regenerative Medicine|April 14, 2025
A Novel Epidermis Model Using Primary Hidradenitis Suppurativa KeratinocytesIsabel Haferland, Andreas Pinter, Tanja Rossmanith, et al.
The Journal of Dermatological Treatment|February 26, 2019
Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trialAndrew Blauvelt, Mark Lomaga, Russel Burge, et al.
Vaccines|August 28, 2021
Influenza Vaccination in Psoriatic Patients-Epidemiology and Patient Perceptions: A German Multicenter Study (Vac-Pso)Christian Kromer, Phoebe Wellmann, Ralf Siemer, et al.
Dermatology (Basel, Switzerland)|December 16, 2020
Coprevalence of Hidradenitis Suppurativa and Psoriasis: Detailed Demographic, Disease Severity and Comorbidity PatternAndreas Pinter, Mana Sarlak, Kim Nicola Zeiner, et al.
International Journal of Cancer|January 19, 2007
Simultaneous blockade of VEGFR-1 and VEGFR-2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formationJens Gille, Regina Heidenreich, Andreas Pinter, et al.
Dermatology and Therapy|June 6, 2020
Hidradenitis Suppurativa and Concurrent Psoriasis: Comparison of Epidemiology, Comorbidity Profiles, and Risk FactorsAndreas Pinter, Georgios Kokolakis, Juergen Rech, et al.
Dermatology and Therapy|May 10, 2024
Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) StudyAndreas Pinter, Ahmed M Soliman, Irina Pivneva, et al.
The Journal of Investigative Dermatology|March 8, 2008
Microtubule-targeted drugs inhibit VEGF receptor-2 expression by both transcriptional and post-transcriptional mechanismsMarkus Meissner, Andreas Pinter, Despina Michailidou, et al.
Dermatology (Basel, Switzerland)|May 21, 2026
PASI Training via Virtual Reality Application - new way of effective teachingSascha Gerd Decker, Falk Ochsendorf, Michael Gairing, et al.
Dermatology (Basel, Switzerland)|November 6, 2024
Brodalumab Is Effective for Psoriasis Patients with Difficult-To-Treat Body Regions: Results from an Observational Clinical StudyStephanie Dauth, Ann Christina Foldenauer, Konstantin Hallmann, et al.
Pageof 14